Insider · CIK 0001448074
Robert J Alpern
director
Files at ABT (ABBOTT LABORATORIES), ABBV (AbbVie Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Stock Equivalent Unitsderivative | +58 | $133.94 | $7,769 | 10,300 | Oct 2, 2025 |
| Sep 30, 2025 | ABBV AbbVie Inc. | AGrant or award Stock Equivalent Unitsderivative | +33 | $231.54 | $7,641 | 10,151 | Oct 2, 2025 |
| Jun 30, 2025 | ABBV AbbVie Inc. | AGrant or award Stock Equivalent Unitsderivative | +40 | $185.62 | $7,425 | 10,038 | Jul 2, 2025 |
| Jun 30, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Stock Equivalent Unitsderivative | +57 | $136.01 | $7,753 | 10,195 | Jul 1, 2025 |
| May 9, 2025 | ABBV AbbVie Inc. | AGrant or award Common Stock, $0.01 par value | +1,203 | $0.00 | $0 | 35,646 | May 13, 2025 |
| Apr 25, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Common shares without par value | +1,635 | $0.00 | $0 | 40,798 | Apr 29, 2025 |
| Mar 31, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Stock Equivalent Unitsderivative | +59 | $132.65 | $7,826 | 10,093 | Apr 2, 2025 |
| Mar 31, 2025 | ABBV AbbVie Inc. | AGrant or award Stock Equivalent Unitsderivative | +35 | $209.52 | $7,333 | 9,907 | Apr 2, 2025 |
| Dec 31, 2024 | ABT ABBOTT LABORATORIES | AGrant or award Stock Equivalent Unitsderivative | +69 | $113.11 | $7,805 | 9,988 | Jan 3, 2025 |
| Dec 31, 2024 | ABBV AbbVie Inc. | AGrant or award Stock Equivalent Unitsderivative | +42 | $177.70 | $7,463 | 9,788 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.